Manufacturing, Biologic Drugs

Oral Delivery of Macromolecular Drugs

July 02, 2018

Macromolecular drugs are typically injected, but oral dosage forms are being developed to improve the treatment of gastrointestinal conditions such as inflammatory bowel disease.

Purolite Launches New Protein A Resin

June 28, 2018

The new resin used a combination of “jetting” technology and a high-performance Protein A ligand.

Waters’ New UPLC Platform Meets Evolving Chromatography Needs

June 25, 2018

Pharmaceutical Technology's In the Lab eNewsletter

The company’s next-generation ultraperformance liquid chromatography platform is designed to meet the evolving laboratory requirements for chromatographic performance.

CellGenix Completes First Step of Facility Expansion for Cell-Culture Reagents

June 22, 2018

The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.

Canada OKs Samsung BioLogics’ mAb Drug Substance Plant

June 21, 2018

The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.

WuXi Biologics to Build US Biologics Production Facility

June 13, 2018

WuXi Biologics will invest $60 Million to establish a biologics production facility in Massachusetts.

GE Healthcare Equips China Cell Therapy Manufacturing Plant with FlexFactory

June 07, 2018

The company will provide the first FlexFactory manufacturing platform for cell therapy manufacturing.

Identifying Contamination: Subvisible Particle Imaging

June 02, 2018

Flow imaging microscopy can be used to identify particulates and their sources.

Bosch to Present New Freeze Dryer at Achema 2018

May 30, 2018

Bosch Packaging Technology will present its new modular freeze dryer at Achema 2018.

GE and CCRM Partner with DiscGenics on New Cell Therapy

May 30, 2018

GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.